Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer

Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer

June 24, 2014

Cambridge, Mass. – Editas Medicine, a transformative genome editing company, today announced the appointment of Katrine S. Bosley as chief executive officer. Ms. Bosley brings to Editas more than 20 years of experience in the biotechnology industry and has been a leader in emerging companies with broad platforms for innovative medicines.

Clinical Chemistry Study Reports on Use of T2MR to Evaluate Hemostasis in Whole Blood

Clinical Chemistry Study Reports on Use of T2MR to Evaluate Hemostasis in Whole Blood

June 23, 2014

-Results Suggest T2MR Has Potential to Provide Rapid and Sensitive Identification of Patients at Risk for Thrombosis and Bleeding-

Syros Pharmaceuticals Co-Founders’ Novel Approach to Cancer Regulation Published in Nature

Syros Pharmaceuticals Co-Founders’ Novel Approach to Cancer Regulation Published in Nature

June 23, 2014

Discovery further validates Syros’ proprietary gene control platform

BIND Therapeutics and Roche Collaborate on Discovery of Novel Nanomedicines

BIND Therapeutics and Roche Collaborate on Discovery of Novel Nanomedicines

June 19, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND's Accurin technology with Roche's proprietary therapeutic payloads and targeting ligands.

Moderna Named to CNBC Disruptor 50 List

Moderna Named to CNBC Disruptor 50 List

June 17, 2014

Messenger RNA TherapeuticsTM leader joins short list of major innovators for potential to transform the treatment of many diseases

Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout

Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout

June 17, 2014

 Selecta's immune tolerance pipeline includes programs in gout, hemophilia A and food allergies

Selecta continues to advance key immune activation programs, with newly-announced funding totaling $9.35 million from the Bill & Melinda Gates Foundation and NIH/NIDA

Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout

Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout

June 17, 2014

3SBio’s pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory and tophaceous gout as well as tumor lysis syndrome

Selecta will combine pegsiticase with its novel immunomodulatory Synthetic Vaccine Particle (SVP™) platform to develop SEL-212, a treatment with improved efficacy and safety

Selecta Biosciences to Accelerate Program for Novel Dual Action Vaccine for Malaria

Selecta Biosciences to Accelerate Program for Novel Dual Action Vaccine for Malaria

June 17, 2014

Grant from the Bill & Melinda Gates Foundation to Leverage Synthetic Nanoparticle Vaccine Platform to Enable Potent, Durable, Dual-Action Vaccines

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia

June 16, 2014

CAMBRIDGE, Mass., Jun 16, 2014 (BUSINESS WIRE) -- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia (AML). AG-221 is an oral, first-in-class IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.

Avedro Becomes Exclusive Global Supplier of MedioCROSS®Riboflavin for Corneal Cross-Linking

Avedro Becomes Exclusive Global Supplier of MedioCROSS®Riboflavin for Corneal Cross-Linking

June 12, 2014

Avedro’s VibeX® and MedioCROSS Are Two of the World’s Leading Ophthalmic Riboflavin Product Brands